

N Lynn Henry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4679941/publications.pdf>

Version: 2024-02-01

101
papers

5,664
citations

117625

34
h-index

82547

72
g-index

101
all docs

101
docs citations

101
times ranked

8094
citing authors

#	ARTICLE	IF	CITATIONS
1	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 611-635.	1.6	651
2	Cancer biomarkers. <i>Molecular Oncology</i> , 2012, 6, 140-146.	4.6	600
3	Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 961-965.	1.6	517
4	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 43-73.	329.8	497
5	Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 936-942.	1.6	313
6	Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 167.	7.4	202
7	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2019, 37, 1956-1964.	1.6	189
8	Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. <i>Clinical Biochemistry</i> , 2016, 49, 1354-1360.	1.9	175
9	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1816-1837.	1.6	139
10	Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast Cancer. <i>Oncologist</i> , 2006, 11, 541-552.	3.7	132
11	Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2487-2498.	7.0	112
12	Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 1474-1486.	1.6	102
13	Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression. <i>American Journal of Psychiatry</i> , 2008, 165, 1251-1255.	7.2	91
14	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. <i>Journal of Clinical Oncology</i> , 2016, 34, 2303-2311.	1.6	80
15	Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor–Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. <i>Journal of Clinical Oncology</i> , 2018, 36, 326-332.	1.6	79
16	Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. <i>Cancer</i> , 2014, 120, 2403-2411.	4.1	76
17	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4184-4193.	1.6	74
18	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5292-5304.	7.0	73

#	ARTICLE	IF	CITATIONS
19	Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer. <i>Oncology</i> , 2006, 71, 168-175.	1.9	68
20	Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 571-575.	2.5	63
21	Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 907-914.	2.5	62
22	Evidence for association of SNPs in <i>ABC1</i> and <i>CBR3</i> , but not <i>RAC2</i> , <i>NCF4</i> , <i>SLC28A3</i> or <i>TOP2B</i> , with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. <i>Pharmacogenomics</i> , 2016, 17, 231-240.	1.3	59
23	Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. <i>Journal of Clinical Oncology</i> , 2020, 38, 2122-2129.	1.6	59
24	Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. <i>Cancer</i> , 2011, 117, 5469-5475.	4.1	58
25	Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. <i>Oncologist</i> , 2016, 21, 539-546.	3.7	56
26	Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. <i>Oncology</i> , 2008, 22, 1401-8.	0.5	52
27	Prediction of Postchemotherapy Ovarian Function Using Markers of Ovarian Reserve. <i>Oncologist</i> , 2014, 19, 68-74.	3.7	51
28	Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 807-816.	2.5	50
29	Disparities in cancer survival and incidence by metropolitan versus rural residence in Utah. <i>Cancer Medicine</i> , 2018, 7, 1490-1497.	2.8	50
30	Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju034-dju034.	6.3	47
31	Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. <i>Molecular Oncology</i> , 2016, 10, 1078-1085.	4.6	43
32	Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 3205-3221.	1.6	43
33	Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. <i>Clinical Cancer Research</i> , 2018, 24, 3602-3610.	7.0	40
34	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). <i>Breast Cancer Research and Treatment</i> , 2018, 172, 603-610.	2.5	37
35	Management of Aromatase Inhibitor-Induced Musculoskeletal Symptoms. <i>JCO Oncology Practice</i> , 2020, 16, 733-739.	2.9	36
36	A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. <i>Cancer</i> , 2010, 116, 4360-4367.	4.1	35

#	ARTICLE	IF	CITATIONS
37	Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 589-595.	2.5	34
38	Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 246.	7.1	34
39	A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2019, 79, 3466-3478.	0.9	32
40	Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study. <i>Supportive Care in Cancer</i> , 2020, 28, 4163-4172.	2.2	31
41	Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3591-3596.	7.0	29
42	Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. <i>Molecular Oncology</i> , 2015, 9, 1868-1876.	4.6	29
43	Effect of Estrogen Depletion on Pain Sensitivity in Aromatase Inhibitor-Treated Women With Early-Stage Breast Cancer. <i>Journal of Pain</i> , 2014, 15, 468-475.	1.4	28
44	Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 263-273.	2.5	27
45	Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 287-297.	2.5	26
46	Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 163-172.	2.5	23
47	Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 395-403.	2.5	19
48	Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registry. <i>Cancer</i> , 2017, 123, 2975-2983.	4.1	19
49	Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202. <i>Cancer</i> , 2019, 125, 2123-2129.	4.1	18
50	Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 168-174.e2.	2.4	16
51	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	2.9	15
52	Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 880-890.	2.4	14
53	Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2021, 113, 989-996.	6.3	13
54	Survey of US Medical Oncologists' Practices and Beliefs Regarding <i>DPYD</i> Testing Before Fluoropyrimidine Chemotherapy. <i>JCO Oncology Practice</i> , 2022, 18, e958-e965.	2.9	13

#	ARTICLE	IF	CITATIONS
55	Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 597-603.	2.5	11
56	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, <i>Research Directions. JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	2.9	11
57	Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2020, 159, 509-514.	1.4	11
58	Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy. <i>Pharmacogenomics</i> , 2021, 22, 145-155.	1.3	11
59	Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation. <i>Clinical Breast Cancer</i> , 2017, 17, 350-355.e4.	2.4	10
60	Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 411-419.	2.5	10
61	Breast cancer histologic subtypes show excess familial clustering. <i>Cancer</i> , 2019, 125, 3131-3138.	4.1	10
62	The Power of the Placebo in Symptom Management. <i>Journal of Clinical Oncology</i> , 2015, 33, 1870-1872.	1.6	9
63	ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. <i>Physiological Genomics</i> , 2016, 48, 688-698.	2.3	9
64	Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study. <i>Breast</i> , 2020, 51, 21-28.	2.2	9
65	Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 453-461.	2.5	8
66	Integrative Oncology Education: An Emerging Competency for Oncology Providers. <i>Current Oncology</i> , 2021, 28, 853-862.	2.2	8
67	Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 662734.	2.3	8
68	Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 659-668.	2.5	7
69	Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry. <i>Cancer</i> , 2017, 123, 948-956.	4.1	7
70	Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. <i>Pharmacogenomics</i> , 2019, 20, 571-580.	1.3	7
71	Thinking beyond the tumor to better understand chronic symptoms in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 413-416.	2.5	6
72	Assessment of PIK3CA Mutations in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Clinical Validity but Not Utility. <i>Journal of Clinical Oncology</i> , 2014, 32, 3207-3209.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Factors influencing the use of extended adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 181-189.	2.5	6
74	Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. <i>Journal of Clinical Oncology</i> , 2021, 39, 3800-3812.	1.6	6
75	Extended Endocrine Therapy: Is 5 Years Enough?. <i>Current Oncology Reports</i> , 2017, 19, 16.	4.0	5
76	Disparities in Cardiovascular Disease Risk Among Hispanic Breast Cancer Survivors in a Population-Based Cohort. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab016.	2.9	5
77	Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer. <i>Oncology</i> , 2007, 21, 1301-9; discussion 1311, 1314, 1319.	0.5	5
78	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 482-484.	2.5	4
79	Cancer-Related Cognitive Impairment or "Chemobrain": Emerging Assessments, Treatments, and Targets for Intervention. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2021, 9, 108-118.	0.8	4
80	Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 116-123.	1.5	4
81	Cardiovascular disease risk in long-term breast cancer survivors: A population-based cohort study. <i>Cancer</i> , 2022, 128, 2826-2835.	4.1	4
82	The pathway to clinical use of a cancer biomarker. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S17-S21.	1.2	3
83	Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 287-294.	2.5	3
84	Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab018.	2.9	3
85	Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 475-483.	2.3	3
86	Identifying Barriers and Facilitators to Scalp Cooling Therapy Through a National Survey of the Awareness, Practice Patterns, and Attitudes of Oncologists. <i>JCO Oncology Practice</i> , 2022, 18, e225-e234.	2.9	3
87	Management of patients with muscle-invasive and metastatic bladder cancer. <i>Oncology</i> , 2005, 19, 1333-42; discussion 1342, 1347, 1350 passim.	0.5	3
88	One size does not fit all: quality of life during adjuvant aromatase inhibitor therapy. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 751-753.	2.5	2
89	Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab087.	2.9	2
90	Muscle Mass Affects Paclitaxel Systemic Exposure and May Inform Personalized Paclitaxel Dosing. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	2

#	ARTICLE	IF	CITATIONS
91	Complexities of adjuvant endocrine therapy in young premenopausal women. <i>Oncology</i> , 2009, 23, 482, 487.	0.5	2
92	CYP2D6 testing for breast cancer patients: is there more to the story?. <i>Oncology</i> , 2009, 23, 1236, 1243, 1249.	0.5	2
93	Bridging the Medical Education and Quality Cancer Care Divide: A Call to Action. <i>Journal of Oncology Practice</i> , 2015, 11, 424-426.	2.5	1
94	Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancer. <i>Future Oncology</i> , 2017, 13, 2507-2510.	2.4	1
95	A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 54.	1.9	1
96	Evaluating the Association of Adverse Events and Patient-Reported Symptoms to Endocrine Therapy Tolerability. <i>Journal of Clinical Oncology</i> , 2022, 40, 430-431.	1.6	1
97	Adjuvant Systemic Therapy for Elderly Women with Breast Cancer. <i>Women's Health</i> , 2006, 2, 75-87.	1.5	0
98	Aromatase inhibitor-associated musculoskeletal pain: taking "AIM"™ at a symptom in breast cancer survivors. <i>Pain Management</i> , 2011, 1, 191-193.	1.5	0
99	Reply to K.I. Pritchard. <i>Journal of Clinical Oncology</i> , 2013, 31, 4476-4477.	1.6	0
100	Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy. <i>Breast Journal</i> , 2019, 25, 1254-1256.	1.0	0
101	Reply to A. Katz. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-103.	1.6	0